Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.47 |
| ▸ | TUBB | P07437 | 1/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.47 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.47 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.47 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.47 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 3/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL30781893 | 0.91 | TUBB4A (0.45) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL31598867 | 0.78 | TUBB4A (0.37) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9464494 | 0.77 | IDH1 (0.44) | BRD4MGLLCMA1NPC1RAB9A | |
| SCHEMBL116788 | 0.76 | HPGD (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL16776508 | 0.76 | TUBB4A (0.36) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL14856800 | 0.76 | HAO1 (0.38) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL26698236 | 0.76 | LMNA (0.46) | ALDH1A1MAPTLMNAKDM4EGAA | |
| SCHEMBL30770309 | 0.75 | CA12 (0.44) | ALDH1A1MAPTCA12CA1CA2 | |
| SCHEMBL22847783 | 0.74 | KDM4E (0.54) | BRD4PTPN1ALDH1A1MAPTKDM4E | |
| SCHEMBL27250557 | 0.74 | MGLL (0.37) | BRD4MGLLALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115362149-A | SHP2 inhibitor and composition and application thereof | 贝达药业股份有限公司 | 2022-11-18 | — | — | CN | claimed |
| US-20250179059-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| CN-116135858-B | Furanopyridone compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2025-04-01 | — | — | CN | disclosed |
| US-12162870-B2 | Anticancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| EP-4351560-A1 | ANTICANCER COMPOUNDS | The Regents of the University of California (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117794525-A | Anticancer compounds | 加利福尼亚大学董事会 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024043319-A1 | ANTIBODY-DRUG COMPLEX | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2024-02-29 | — | — | WO | disclosed |
| WO-2023088493-A1 | FURO-PYRIDONE COMPOUND AND USE THEREOF | 中国科学院广州生物医药与健康研究院 | 2023-05-25 | — | — | WO | disclosed |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-01-26 | — | — | US | disclosed |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-01-26 | — | — | US | disclosed |
| US-20160016966-A1 | FUROPYRIDINES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-21 | — | — | US | disclosed |
| EP-2970323-A1 | FUROPYRIDINES AS BROMODOMAIN INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2016-01-20 | — | — | EP | disclosed |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-09-03 | — | — | US | disclosed |
| WO-2014140077-A1 | FUROPYRIDINES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| US-7399320-B2 | Use of tetra-azapentamethine compounds as direct dyeing agents and novel tetra-azapentamethine compounds | L'OREAL (FR) | 2008-07-15 | — | — | US | disclosed |
| US-20080092307-A1 | Use of tetra-azapentamethine compounds as direct dyeing agents and novel tetra-azapentamethine compounds | L'OREAL (FR) | 2008-04-24 | — | — | US | disclosed |
| US-7311736-B2 | Use of tetra-azapentamethine compounds as direct dyeing agents and novel tetra-azapentamethine compounds | L'OREAL (FR) | 2007-12-25 | — | — | US | disclosed |
| WO-2007006591-A2 | DIHALOGENATION OF N,O-DISUBSTITUTED HYDROXIPYRIDONES AND USES THEREOF | BAYER CROPSCIENCE SA (FR) | 2007-01-18 | — | — | WO | disclosed |
| US-20050028300-A1 | Use of tetra-azapentamethine compounds as direct dyeing agents and novel tetraazapentamethine compounds | L'OREAL (FR) | 2005-02-10 | — | — | US | disclosed |
| US-4898654-A | IRRADIATING INCLUSION COMPLEX | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1990-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179059-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | TUBB4A 1290/4885TUBB 782/4885TUBA3C 1307/4885 |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | TUBB4A 1290/4885TUBB 782/4885TUBA3C 1307/4885 |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | TUBB4A 1356/4885TUBB 550/4885TUBA3C 695/4885 |
| US-20050028300-A1 | Use of tetra-azapentamethine compounds as direct dyeing agents and novel tetraazapentamethine compounds | KRT18, TET1, DNMT1 | TUBB4A 8/4885TUBB 7/4885TUBA3C 38/4885 |
| US-20080092307-A1 | Use of tetra-azapentamethine compounds as direct dyeing agents and novel tetra-azapentamethine compounds | KRT18, TUBA4A, TUBB4A | TUBB4A 3/4885TUBB 9/4885TUBA3C 31/4885 |
| US-20160016966-A1 | FUROPYRIDINES AS BROMODOMAIN INHIBITORS | BRD3, BRD4, BRPF3 | TUBB4A 1107/4885TUBB 405/4885TUBA3C 912/4885 |
| US-12162870-B2 | Anticancer compounds | BET1, BRD4, BICRA | TUBB4A 1290/4885TUBB 782/4885TUBA3C 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.